TLDR
- SPRC shares drop nearly 12% after SciSparc announces MUSE device acquisition
- SciSparc broadens strategy with planned MUSE™ endoscopic technology purchase
- Stock slides as SciSparc moves to commercialize patented GERD treatment device
- SciSparc targets global GERD market through strategic MUSE system acquisition
- SPRC dips as company adds endoscopic IP to accelerate medical device revenues
SciSparc Ltd. (SPRC) shares fell nearly 12% to $1.2780 after a $0.1720 decline. The pullback followed disclosure of a definitive agreement expanding medical device operations. SciSparc Ltd. announced plans to acquire patented endoscopic technologies supporting near-term commercialization.
Stock performance reflects session decline and corporate update
SPRC traded lower after the stock retreated about 11.86% during the session. The decline followed a prior higher price, reflecting increased trading activity and repositioning. However, the company maintained focus on operational expansion alongside market volatility.
The stock movement occurred as the company detailed its strategic shift beyond clinical pharmaceuticals. SciSparc Ltd. operates through NeuroThera Labs while adding medical device assets. The announcement broadened the company profile during a volatile trading period.
Market activity reflected the timing of the announcement rather than operational changes. SPRC continued to outline its long-term growth plans. Trading volumes adjusted as participants assessed the expanded business scope.
Acquisition terms outline intellectual property expansion
SciSparc Ltd. agreed to acquire patents, trademarks, and know-how from Xylo Technologies. The assets center on innovative endoscopic systems and advanced medical camera technologies. Notably, the portfolio includes the MUSE system for GERD treatment.
The MUSE system serves as a single-use endoscopic device for transoral fundoplication procedures. This minimally invasive approach targets gastroesophageal reflux disease with established clinical use. SciSparc Ltd. plans immediate commercialization following transaction closing.
In consideration, the company will issue shares representing 19.99% of outstanding capital. The closing date is set for March 8, 2026, subject to customary conditions. Alternatively, SciSparc Ltd. may issue pre-funded warrants at its discretion.
Commercial strategy targets global GERD device market
SPRC aims to replicate Xylo’s prior licensing success in Greater China. Xylo previously received $3 million through a regional distribution agreement in 2019. Therefore, the company plans similar exclusive partnerships across multiple regions.
Targeted territories include North America, Europe and Latin America with established distributors. SciSparc Ltd. expects partnerships to support faster market entry. This approach aligns with revenue generation goals tied to medical device commercialization.
Market research values the global GERD device market at $2.5 billion in 2024. Forecasts project growth to $3.03 billion by 2030 with a 3.24% CAGR. Thus, SciSparc Ltd. positions itself within a steadily expanding healthcare segment.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
